Schouw & Co (SCHO) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
9 Nov, 2026Executive summary
Record Q3 revenue rose 16% to DKK 10,646m and EBITDA rose 37% to DKK 1,199m, reflecting broad-based improvements from higher activity, operating leverage and efficiency.
Profit before tax increased 69% to DKK 881m; strong results and backlogs supported higher FY 2026 guidance.
Financial highlights
Q3 EBIT rose 51% to DKK 894m; profit for the period was DKK 663m versus DKK 375m a year earlier.
9M revenue increased 6% to DKK 27,310m and EBITDA rose 22% to DKK 2,618m.
Q3 operating cash flow increased to DKK 966m from DKK 894m; 9M operating cash flow was DKK 1,402m versus DKK 1,656m, reflecting higher working-capital needs.
Outlook and guidance
FY 2026 revenue guidance increased to DKK 36,200–38,100m and EBITDA to DKK 3,375–3,525m; profit before tax is forecast at DKK 2,015–2,165m.
BioMar raised revenue guidance to DKK 17,800–18,600m and EBITDA to DKK 1,720–1,790m; GPV raised guidance to DKK 8,800–9,200m revenue and DKK 740–770m EBITDA.
HydraSpecma maintained revenue guidance at DKK 3,400–3,600m and raised EBITDA to DKK 445–465m; Fibertex Nonwovens raised guidance to DKK 2,600–2,700m revenue and DKK 280–300m EBITDA.
Fibertex Personal Care raised EBITDA guidance to DKK 170–190m; Borg Automotive narrowed revenue guidance to DKK 1,600–1,700m and raised EBITDA to DKK 95–110m.
Spectre 2026 guidance covers four months, with revenue of DKK 300–400m and EBITDA around break-even; 2030 ambition is DKK 1.7–2.0bn revenue and 15%–17% EBITDA.
Latest events from Schouw & Co
- 2030 targets DKK 4.5bn EBITDA, with portfolio growth and disciplined investment.SCHO
CMD 2026 presentation - 2026 guidance raised after strong Q2 growth, margin gains, and key portfolio moves.SCHO
Q2 2026 - EBITDA up 5% and profit before tax up 36% YoY, guidance maintained, BioMar IPO advancing.SCHO
Q1 2026 - Record cash flow and EBITDA growth in most segments, with improved leverage and strong 2026 outlook.SCHO
Q4 2025 - Stable Q2 with strong cash flow and narrowed guidance; segment outlooks mixed amid volatility.SCHO
Q2 2025 - Revenue and EBITDA fell, but profitability held as cost cuts and a BioMar IPO review drive strategy.SCHO
Q3 2024 - EBITDA guidance raised as margin gains offset revenue decline amid market headwinds.SCHO
Q2 2024 - Q1 2025 revenue up 1%, EBITDA down 13%, guidance maintained, BioMar IPO prep advances.SCHO
Q1 2025 - EBITDA rose 3% to a record DKK 2.93bn despite a 7% revenue drop and strong cash flow.SCHO
Q4 2024